Manufacturer record
Habitare Pharma Pvt.Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Habitare Pharma Pvt.Ltd (Himachal Pradesh) was declared Not of Standard Quality in September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: HT25871, Aceclofenac, Paracetamol &Chlorozoxazone Tablets (exp Nov 2027). State Lab, DCL, Telangana (state lab) found it not of standard quality: Sample FENELA-MR tablets does not comply test for Disintegration as per IP 2022. Listed in the September 2026 alert.
Records by type
1 record linked to Habitare Pharma Pvt.Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Aceclofenac, Paracetamol &Chlorozoxazone Tablets | Batch HT25871Mfg Dec 2025 · Exp Nov 2027 | Sample FENELA-MR tablets does not comply test for Disintegration as per IP 2022Disintegration | State Lab, DCL, TelanganaState lab | Sep 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.